Jama Clinical Reviews: Interviews About Ideas & Innovations In Medicine, Science & Clinical Practice. Listen & Earn Cme Credi

CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott, MD, to discuss "CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.” Related Content: CAR T Cells and T-Cell Therapies for Cancer Translational Science Reviews—A New JAMA Review